|
|
 |
Dr. Ben Vollrath
Dr. Vollrath is a drug discovery scientist and entrepreneur and joined Avalon Ventures in February 2007 as an Entrepreneur in Residence. His efforts are focused on identifying and developing seed and early-stage investment opportunities in the biotechnology arena. Recently, he co-founded three Avalon VIII portfolio companies, aFRAXis, Carolus Therapeutics and Otonomy, and is currently actively involved in developing the drug discovery and development efforts in these companies. In addition, Dr. Vollrath is a scientific consultant to Zacharon Pharmaceuticals, also an Avalon VIII portfolio company.
Prior to his engagement at Avalon, Dr. Vollrath was an Associate Director of Business Development at Orphagen Pharmaceuticals, a San Diego-based early stage biotechnology company. In this role, Dr. Vollrath was involved in preparing the company for a venture capital funding round. Prior to Orphagen, Dr. Vollrath was a Research Scientist at Renovis, a San Francisco-based drug development company. He was a project leader for a lead compound identification campaign and led the genomics efforts of the company.
Dr. Vollrath did Postdoctoral studies at Merck with Dr. Edward Scolnick and was a Visiting Research Fellow at the Department of Genetics, Harvard Medical School with Dr. Philip Leder. Dr. Vollrath received his PhD in Molecular and Cellular Biology from the University of Tuebingen (Germany) and a Master of Science in Chemistry from the University of Heidelberg (Germany).
|
|
